BSE Live
Mar 17, 16:01Prev. Close
6074.90
Open Price
6073.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 17, 15:57Prev. Close
6071.00
Open Price
6074.00
Bid Price (Qty.)
6086.50 (7)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Divis Laboratories (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 1,072.08 | 990.92 | 781.24 | 680.63 | 472.37 | |
| Net CashFlow From Operating Activities | 826.33 | 556.75 | 464.68 | 338.36 | 326.55 | |
| Net Cash Used In Investing Activities | -520.84 | -305.15 | -239.29 | -204.41 | -221.31 | |
| Net Cash Used From Financing Activities | -302.95 | -248.50 | -230.73 | -131.11 | -104.16 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 2.54 | 3.10 | -5.33 | 2.84 | 1.09 | |
| Cash And Cash Equivalents Begin of Year | 15.09 | 11.99 | 17.32 | 14.48 | 13.39 | |
| Cash And Cash Equivalents End Of Year | 17.62 | 15.09 | 11.99 | 17.32 | 14.48 |
25.02.2026
Divis Labs Consolidated December 2025 Net Sales at Rs 2,604.00 crore, up 12.29% Y-o-Y
25.02.2026
Divis Labs Standalone December 2025 Net Sales at Rs 2,578.00 crore, up 12.23% Y-o-Y
12.02.2026
Accumulate Divis Laboratories; target of Rs 6850: Prabhudas Lilladher
20.11.2025
Accumulate Divis Laboratories; target of Rs 6795: Deven Choksey
25.02.2026
Divis Labs Consolidated December 2025 Net Sales at Rs 2,604.00 crore, up 12.29% Y-o-Y
25.02.2026
Divis Labs Standalone December 2025 Net Sales at Rs 2,578.00 crore, up 12.23% Y-o-Y
14.11.2025
Divis Labs Consolidated September 2025 Net Sales at Rs 2,715.00 crore, up 16.12% Y-o-Y
12.11.2025
Divis Labs Standalone September 2025 Net Sales at Rs 2,660.00 crore, up 15.55% Y-o-Y
24.05.2024
Divi's Labs Q4 preview: Revenue, net profit to grow on normalised base, better product mix
04.11.2023
Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix
14.08.2023
Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery
19.05.2023
Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill
17.03.2026
Zydus, Lupin sign agreement to co‑market weight-loss semaglutide injection in India
17.03.2026
16.03.2026
15.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth